Abstract:BackgroundKaposiform lymphangiomatosis (KLA) is a complex lymphatic anomaly involving most commonly the mediastinum, lung, skin and bones with few effective treatments. In recent years, RAS-MAPK pathway mutations were shown to underlie the pathogenesis of several complex lymphatic anomalies. Specifically, an activating NRAS mutation (p.Q61R) was found in the majority of KLA patients. Recent reports demonstrated promising results of treatment with the MEK inhibitor, Trametinib, in patients with complex lymphatic anomalies harboring gain of function mutations in ARAF and SOS1, as well as loss of function mutation in the CBL gene, a negative regulator of the RAS-MAPK pathway. We present a 9-year-old child with a severe case of KLA harboring the typical NRAS (p.Q61R) mutation detected by plasma-derived cell free DNA, responsive to trametinib therapy.MethodsThe NRAS somatic mutation was detected from plasma cfDNA using droplet digital PCR. Concurrent in-vitro studies of trametinib activity on mutant NRAS affected lymphatic endothelial cells were performed using a three-dimensional spheroid sprouting assay.ResultsTrametinib treatment lead to resolution of lifelong thrombocytopenia, improvement of pulmonary function tests and wellbeing, as well as weaning from prolonged systemic steroid treatment. Concurrent studies of mutant NRAS-expressing cells showed enhanced lymphangiogenic capacity along with over activation of the RAS-MAPK and PI3K-AKT-mTOR pathways, both reversed by trametinib.ConclusionsTrametinib treatment can substantially change the prognosis of patients with RAS pathway associated lymphatic anomalies.ImpactThis is the first description of successful trametinib treatment of a patient with KLA harboring the most characteristic NRAS p.Q61R mutation.Treatment can significantly change the prognosis of patients with RAS pathway-associated lymphatic anomalies.We devised an in vitro model of KLA enabling a reproducible method for the continued study of disease pathogenesis.Mutated NRAS p.Q61R cells demonstrated increased lymphangiogenic capacity.

Lymphatic endothelial cell-specific NRAS p.Q61R mutant embryos show abnormal lymphatic vessel morphogenesis

NRASQ61R mutation drives elevated angiopoietin‐2 expression in human endothelial cells and a genetic mouse model

Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition

Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition

Foxc1 and Foxc2 Deletion Causes Abnormal Lymphangiogenesis and Correlates with ERK Hyperactivation.

Abnormal Lymphatic Vessel Development in Neuropilin 2 Mutant Mice.

Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations

A high-throughput zebrafish screen identifies novel candidate treatments for Kaposiform Lymphangiomatosis (KLA)

LMBR1L regulates the proliferation and migration of endothelial cells through Norrin/β-catenin signaling

The Ras Guanyl Nucleotide-Releasing Protein Rasgrp1 is Involved in Lymphatic Development in Zebrafish

Neuropilin-2 Mediates VEGF-C–induced Lymphatic Sprouting Together with VEGFR3

Lymphatic endothelial-cell expressed ACKR3 is dispensable for postnatal lymphangiogenesis and lymphatic drainage function in mice

LMBR1L regulates the proliferation and migration of endothelial cells through Norrin/beta-catenin signaling

Loss of Lgl1 Disrupts the Radial Glial Fiber-guided Cortical Neuronal Migration and Causes Subcortical Band Heterotopia in Mice

Activated N-Ras Signaling Regulates Arterial-Venous Specification in Zebrafish

Small GTPase Rap1A/B Is Required for Lymphatic Development and Adrenomedullin-Induced Stabilization of Lymphatic Endothelial Junctions

Insights Image for "Treatment of severe Kaposiform Lymphangiomatosis positive for NRAS mutation by MEK-inhibition"

-mutant Schwann cells divert to a repair phenotype to induce congenital demyelinating neuropathy

Heterozygous Mutation of Vegfr3 Reduces Renal Lymphatics without Renal Dysfunction

Somatic KRAS mutation in an infant with linear nevus sebaceous syndrome associated with lymphatic malformations: A case report and literature review

Separating Genetic and Hemodynamic Defects in Neuropilin 1